Stereochemical sensitivity of the human UDP-glucuronosyltransferases 2B7 and 2B17

Journal of Medicinal Chemistry

Volumn 49, Issue 5, 2006, Pages 1818-1827

  Bichlmaier, Ingo ^a   Siiskonen, Antti ^a   Finel, Moshe ^a   Yli Kauhaluoma, Jari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 14; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B17; GLUCURONOSYLTRANSFERASE 2B7; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CHIRALITY; ENANTIOMER; ENZYME ANALYSIS; ENZYME SUBSTRATE; GLUCURONIDATION; HUMAN; ISOTOPE LABELING; STEREOCHEMISTRY; SYNTHESIS;

ALCOHOLS; ANTHRACENES; CATALYSIS; CHROMANS; GLUCURONOSYLTRANSFERASE; HUMANS; INDANS; NAPHTHALENES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY; TETRALONES;

EID: 33644855536     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051142c     Document Type: Article

References (41)

1. Parascandola, J. The Evolution of Stereochemical Concepts in Pharmacology. In van't Hoff-LeBell Centennial; Ramsay, O. B., Ed.; American Chemical Society: Washington, DC, 1975; pp 143-158.
2. Crossley, R. Chirality and the Biological Activity of Drugs; CRC Press: Boca Raton, FL. 1995; 196 pp.
3. Eichelbaum, M.; Testa, B.; Somogyi, A. Stereochemical Aspects of Drug Action and Disposition; Springer-Verlag: Berlin, 2003; 442 pp.
4. Federsel, H. J. Asymmetry on large scale: the roadmap to stereoselective processes. Nat. Rev. Drug Discovery 2005, 4, 685-697.
5. Ariëns, E. J. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur. J. Clin. Pharmacol. 1984, 26, 663-668.
6. Agranat, I.; Caner, H.; Caldwell, A. Putting chirality to work: the strategy of chiral switches. Nat. Rev. Drug Discovery 2002, 1, 753-768.
7. Caldwell, J. Do single enantiomers have something special to offer?. Hum. Psychopharmacol. 2001, 16, S67-S71.
8. Handley, D. A. The therapeutic advantages achieved through single-isomer drugs. Pharm. News 1999, 6, 11-15.
9. Fisher, M. B.; Paine, M. F.; Strelevitz, T. J.; Wrighton, S. A. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev. 2001, 33, 273-297.
10. Inman, W. H.; Rawson, N. S. Zomepirac and cardiovascular deaths. Lancet 1983, 2, 908.
11. Kilpatrick, G. J.; Smith, T. W. Morphine-6-glucuronide: actions and mechanisms. Med. Res. Rev. 2005, 25, 521-544.
12. Wells, P. G.; Mackenzie, P. I.; Chowdhury, J. R.; Guillemette, C.; Gregory, P. A.; Ishii, Y.; Hansen, A. J.; Kessler, F. K.; Kim, P. M.; Chowdhury, N. R.; Ritter, J. K. Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug Metab. Dispos. 2004, 32, 281-290.
13. King, C. D.; Rios, G. R.; Green, M. D.; Tephly, T. R. UDP-glucuronosyltransferases. Curr. Drug Metab. 2000, 1, 143-161.
14. Ritter, J. K.; Chen, F.; Sheen, Y. Y.; Tran, H. M.; Kimura, S.; Yeatman, M. T.; Owens, I. S. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J. Biol. Chem. 1992, 267, 3257-3261.
15. Monaghan, G.; Clarke, D. J.; Povey, S.; See, C. G.; Boxer, M.; Burchell, B. Isolation of a human YAC contig encompassing a cluster of UGT2 genes and its regional localization to chromosome 4q13. Genomics 1994, 23, 496-499.
16. The carboxyl-terminal portions of UGT1A isoforms are identical due to exon sharing during transcription and RNA processing. In contrast, the human UGT2B proteins are encoded by individual genes on chromosome 4, but the C-terminal halves of the different UGT2B isoforms display high sequence similarities.
17. Luukkanen, L.; Taskinen, J.; Kurkela, M.; Kostiainen, R.; Hirvonen, J.; Finel, M. Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases. Drug Metab. Dispos. 2005, 33, 1017-1026.
18. Meech, R.; Mackenzie, P. I. Structure and function of uridine diphosphate glucuronosyltransferases. Clin. Exp. Pharmacol. Physiol. 1997, 24, 907-915.
19. Sorich, M. J.; Miners, J. O.; McKinnon, R. A.; Smith, P. A. Multiple pharmacophores for the investigation of human UDP-glucuronosyltransferase isoform substrate selectivity. Mol. Pharmacol. 2004, 65, 301-308.
20. Sorich, M. J.; McKinnon, R. A.; Miners, J. O.; Winkler, D. A.; Smith, P. A. Rapid prediction of chemical metabolism by human UDP-glucuronosyltransferase isoforms using quantum chemical descriptors derived with the electronegativity equalization method. J. Med. Chem. 2004, 47, 5311-5317.
21. Turgeon, D.; Carrier, J. S.; Levesque, E.; Hum, D. W.; Belanger, A. Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 2001, 142, 778-787.
22. Turgeon, D.; Carrier, J. S.; Chouinard, S.; Belanger, A. Glucuronidation activity of the UGT2B17 enzyme toward xenobiotics. Drug Metab. Dispos. 2003, 31, 670-676.
23. Court, M. H.; Duan, S. X.; Guillemette, C.; Journault, K.; Krishnaswamy, S.; von Moltke, L. L.; Greenblatt, D. J. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab. Dispos. 2002, 30, 1257-1265.
24. Bichlmaier, I.; Siiskonen, A.; Finel, M.; Yli-Kauhaluoma, J. Chiral distinction between the enantiomers of bicyclic alcohols by UDP- glucuronosyltransferases 2B7 and 2B17. Biol. Chem., in press.
25. Gentili, F.; Bousquet, O.; Brasili, L.; Dontenwill, M.; Feldman, J.; Ghelfi, F.; Giannella, M.; Piergentili, A.; Quaglia, W.; Pigini, M. Imidazoline binding sites (IBS) profile modulation: key role of the bridge in determining I1-IBS or I2-IBS selectivity within a series of 2-phenoxymethylimidazoline analogues. J. Med. Chem. 2003, 46, 2169-2176.
26. Johansen, T. N.; Stensbol, T. B.; Nielsen, B.; Vogensen, S. B.; Frydenvang, K.; Slok, F. A.; Brauner-Osborne, H.; Madsen, U.; Krogsgaard-Larsen, P. Resolution, configurational assignment, and enantiopharmacology at glutamate receptors of 2-amino-3-(3-carboxy-5-methyl-4-isoxazolyl)propionic acid (ACPA) and demethyl-ACPA. Chirality 2001, 13, 523-532.
27. 2 antagonism in a series of 5-substituted trans-1-piperazino-3-phenylindans. J. Med. Chem. 1993, 36, 2761-2770.
28. Corey, E. J.; Bakshi, R. K.; Shibata, S. Highly enantioselective borane reduction of ketones catalyzed by chiral oxazaborolidines. Mechanism and synthetic implications. J. Am. Chem. Soc. 1987, 109, 5551-5553.
29. Corey, E. J.; Helal, C. J. Reduction of carbonyl compounds with chiral oxazaborolidine catalysts: a new paradigm for enantioselective catalysis and a powerful new synthetic method. Angew. Chem., Int. Ed. 1998, 37, 1986-2012.
30. Garrett, C. E.; Prasad, K.; Repic, O.; Blacklock, T. J. The enantioselective reduction of 2′-fluoroacetophenone utilizing a simplified CBS-reduction procedure. Tetrahedron: Asymmetry 2002, 13, 1347-1349.
31. Xu, J.; Wei, T.; Zhang, Q. Influences of electronic effects and anions on the enantioselectivity in the oxazaborolidine-catalyzed asymmetric borane reduction of ketones. J. Org. Chem. 2004, 69, 6860-6866.
32. Salunkhe, A. M.; Burkhardt, E. R. Highly enantioselective reduction of prochiral ketones with N,N-diethylaniline borane (DEANB) in oxazaborolidine- catalyzed reductions. Tetrahedron Lett. 1997, 38, 1523-1526.
33. Barlow, R. B.; Franks, F. M.; Pearson, J. D. M. Relation between biological activity and degree of resolution of optical isomers. J. Pharm. Pharmacol. 1972, 24, 753-761.
34. The authors prefer the term "diastereoselective glucuronidation" over "enantioselective glucuronidation," although the latter is often encountered in the literature. However, the products of the UGT-catalyzed glucuronidation, the glucuronide of the (R)-enantiomer and the glucuronide of its respective (S)-enantiomer, are related as diastereomers. Therefore, the UGT-catalyzed conjugation is diastereoselective provided that the formation of one of the two diastereomers is favored (Moss, G. P. Basic Terminology of Stereochemistry (IUPAC Recommendations 1996). Pure Appl. Chem. 1996, 68, 2193-2222). This preferential formation of one diastereomer over the other is also termed substrate-product stereoselectivity or substrate-product stereospecificity.
35. 14C]UDPG1cA as well as to minimize the radioactive waste output.
36. Kaivosaari, S.; Salonen, J. S.; Mortensen, J.; Taskinen, J. High-performance liquid chromatographic method combining radiochemical and ultraviolet detection for determination of low activities of uridine 5′-diphosphate-glucuronosyltransferase. Anal. Biochem. 2001, 292, 178-187.
37. Agranat, I.; Sarel, S. Reflections on chiral discrimination. Discrimination is between equals, distinction is between unequals. Enantiomer 1996, 1, 249-250.
38. Pfeiffer, C. C. Optical isomerism and pharmacological action, a generalization. Science 1956, 124, 29-31.
39. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
40. The maximum inhibition attained by the enantiomers of the lipophilic alcohols 11-13 ranged merely between 9.1% and 55%, even though the scopoletin concentration was lowered to 50 μM. However, the enantiomers of each compound showed similar inhibition levels at the highest concentration of 0.10 mM. Therefore, the enantiomers of these lipophilic compounds exerted similar affinities to the enzymes (cf. Supporting Information).
41. Kurkela, M.; Garcia-Horsman, J. A.; Luukkanen, L.; Mörsky, S.; Taskinen, J.; Baumann, M.; Kostiainen, R.; Hirvonen, J.; Finel, M. Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme. J. Biol. Chem. 2003, 278, 3536-3544.